Glesatinib companion diagnostic - Mirati Therapeutics/Foundation Medicine

Drug Profile

Glesatinib companion diagnostic - Mirati Therapeutics/Foundation Medicine

Latest Information Update: 15 Mar 2016

Price : $50

At a glance

  • Originator Foundation Medicine
  • Developer Foundation Medicine; Mirati Therapeutics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 21 Dec 2015 Mirati Therapeutics announces intention to submit PMA to the US FDA concurrent with the NDA filing for glesatinib
  • 21 Dec 2015 Mirati Therapeutics and Foundation Medicine collaborate to develop companion diagnostic for glesatinib in USA for Non-small cell lung cancer
  • 01 Oct 2015 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Diagnosis, Second-line therapy or greater) in USA, Australia, South Korea (unspecified route) (NCT02544633; 9192583)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top